MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer
Cell Reports · 2023-10 · 42 (10) · 113221
DOI: 10.1016/j.celrep.2023.113221 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2023-10. Verfasst von Preston D Crowell und 24 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Biology Interdepartmental Program, University of California, Los Angeles, Los Angeles, CA 90095, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIDDK NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Biology Interdepartmental Program, University of California, Los Angeles, Los Angeles, CA 90095, USA.
- Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA 90095, USA.
- Department of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, CA 90095, USA.
- Division of Endocrinology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
- Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 9009…
- Department of Pathology & Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Förderung
- NCI NIH HHS
- NIDDK NIH HHS
- NCATS NIH HHS
- NIGMS NIH HHS
- NIH HHS
- U.S. Department of Defense
- American Cancer Society
- National Cancer Institute
Zitieren
APA
Crowell, P. D., Giafaglione, J. M., Jones, A. E., Nunley, N. M., Hashimoto, T., Delcourt, A. M. L., Petcherski, A., Agrawal, R., Bernard, M. J., Diaz, J. A., Heering, K. Y., Huang, R. R., Low, J. Y., Matulionis, N., Navone, N. M., Ye, H., Zoubeidi, A., Christofk, H. R., Rettig, M. B., …, & Goldstein, A. S. (2023). MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer. Cell Reports, 42(10), 113221. https://doi.org/10.1016/j.celrep.2023.113221
Vancouver
Crowell PD, Giafaglione JM, Jones AE, Nunley NM, Hashimoto T, Delcourt AML, et al. MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer. Cell Reports. 2023;42(10):113221. doi:10.1016/j.celrep.2023.113221
BibTeX
@article{Crowell2023,
author = {Crowell, Preston D and Giafaglione, Jenna M and Jones, Anthony E and Nunley, Nicholas M and Hashimoto, Takao and Delcourt, Amelie M L and Petcherski, Anton and Agrawal, Raag and Bernard, Matthew J and Diaz, Johnny A and Heering, Kylie Y and Huang, Rong Rong and Low, Jin-Yih and Matulionis, Nedas and Navone, Nora M and Ye, Huihui and Zoubeidi, Amina and Christofk, Heather R and Rettig, Matthew B and Reiter, Robert E and Haffner, Michael C and Boutros, Paul C and Shirihai, Orian S and Divakaruni, Ajit S and Goldstein, Andrew S},
title = {MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer},
journal = {Cell Reports},
year = {2023},
volume = {42},
number = {10},
pages = {113221},
doi = {10.1016/j.celrep.2023.113221}
}
EUVIMED